49 results about "Nucleated cell" patented technology

The invention provides an application of a histone deacetylase (HDAC) inhibitor and / or a JAK2 inhibitor in inducing hematopoietic stem progenitor cells, mononuclear cells or total nucleated cells to generate megakaryocytes and / or megakaryocyte progenitor cells. The invention also provides methods of inducing hematopoietic stem progenitor cells, mononuclear cells or total nucleated cells to produce megakaryocytes and / or megakaryocyte progenitor cells comprising exposing the cells to an HDAC inhibitor, and / or exposing the cells to a JAK2 inhibitor.

The application provides a method for detecting HES1 markers of melanoma CTCs by using multiplex immunofluorescence technology, and the method comprises the following steps: S1, collecting peripheral blood of a melanoma patient, and performing sorting and enrichment of CTCs through a microfluidic chip; S2, fixing and permeating after making all nucleated cells in the blood flatly and enriched on an adherent slide through a centrifuge; and sequentially performing co-incubation of HES1, HMB45 and CD45 antibodies on the screened melanoma CTCs through the multiplex immunofluorescence technology, and further analyzing the expression of the HES1 antibody and performing image analysis and quantification. The method is simple in operation, high in detection accuracy, can avoid false negatives and the like, and improves the screening accuracy of melanoma CTCs.

The utility model discloses a rapid mononuclear cell separation tube capable of being easily filled with a partition plate, and belongs to the technical field of cell separation, the rapid mononuclear cell separation tube comprises a centrifugal tube and the partition plate provided with three supporting legs, the partition plate is provided with a peripheral through hole, and the side wall of the bottom in the centrifugal tube is provided with a flange surrounding the axis of the centrifugal tube; a supporting cover is arranged at the open end of the centrifugal tube, a supporting rod moving in the axis direction of the centrifugal tube is arranged on the supporting cover, and a tray used for supporting the partition plate and driving the partition plate to move relative to the centrifugal tube in parallel is arranged at the end, located in the centrifugal tube, of the supporting rod. The tray is provided with a protrusion matched with the peripheral through hole, the protrusion is provided with an air hole which is the same as the peripheral through hole and penetrates through the tray, and the device has the advantages that the partition plate can be rapidly and accurately filled under the condition that it is guaranteed that the partition plate is relatively parallel to the inner diameter of the centrifugal tube, the filling efficiency is greatly improved, and the partition plate and the centrifugal tube are firmly fixed.

Disclosed are methods for culturing coronavirus particles in early syncytiotrophoblasts (eSTBs). The derived eSTBs are mononucleated or bi-nucleated cells with high ACE2 expression and are not multi-n

The utility model relates to the field of centrifugal tubes, in particular to a centrifugal tube for separating nucleated cells and a matched adapter set. The centrifugal tube comprises a centrifugal tube body and an adapter arranged in the centrifugal tube body. The adapter comprises a contracted pipe piece, a positioning piece and an abutting piece. The pipe diameter of the centrifugal pipe can be reduced through the through hole formed in the pipe reducing piece, so that the nucleated cell layer is thickened. The positioning piece comprises a positioning block, a sliding plate and a connecting plate; and by pushing the sliding plate, the connecting plates at the two ends are clamped to the upper ends and the lower ends of the two positioning blocks correspondingly, so that the contracted pipe fitting is positioned. According to the utility model, the column body is adjusted between the two vertically adjacent positioning blocks, and the sliding plates are respectively pushed towards two sides, so that the connecting plates at two ends of the sliding plates are respectively clamped at the upper ends and the lower ends of the two positioning blocks, and the positioning of the column body is completed. After centrifugation is completed, a nucleated cell layer appears in the through hole, the inner diameter of the centrifugal tube can be reduced, and the nucleated cell layer is thickened, so that the nucleated cell layer is conveniently and accurately sucked out.

The invention discloses an immunofluorescence staining method for karyocytes in blood. When immunofluorescence staining is carried out, polylysine is used for treating a cell slide, and then the cell is fixed and smeared and dried, so that the cell and the slide are attached more tightly. The problem that cells fall off in the cleaning process can be effectively avoided. Meanwhile, non-blood cells in the blood sample can be effectively reserved.

The utility model relates to a cord blood hematopoietic stem cell collection, preparation and cryopreservation integrated quadruple bag which comprises a blood collection bag, a preparation bag, a plasma bag and a cryopreservation bag, and the blood collection bag is connected with the preparation bag through a first catheter and a first three-way pipe; a first flow stopping clip is arranged on the second catheter connected between the preparation bag and the first three-way pipe; the first three-way pipe is respectively connected with the plasma bag and the cryopreservation bag through a second conduit and a second three-way pipe; a second flow stopping clip is arranged on the second catheter; a third flow stopping clip is arranged on the fourth catheter connected between the plasma bag and the second three-way pipe; and a fourth flow stopping clip is arranged on the fifth catheter connected between the second three-way pipe and the cryopreservation bag. The quadruple bag is more convenient to extract cells, the cost is reduced, the consumed time is less, the recovery rate of nucleated cells is high, and the separation effect is better.

The present invention relates to a bone marrow fluid analysis method, a sample analysis device, and a recording medium containing a program. The present invention provides a means for obtaining an index related to bone marrow nucleated cell density by measuring nucleated cells and lipid particles in bone marrow fluid. By counting the number of nucleated cells and lipid particles in bone marrow fluid and obtaining an index related to bone marrow nucleated cell density based on the nucleated cell and lipid particle counts, the aforementioned technical problems are solved.

The disclosure provides methods for detecting circular endothelial cells (CECs) in a non-enriched blood sample. The present disclosure is based, in part, on the unexpected discovery that CECs can be detected in non-enriched blood samples. The present disclosure is further based, in part, on the discovery that CECs can be detected in non-enriched blood samples by combining the detection of one or more immunofluorescent markers in the nucleated cells of a non-enriched blood sample with an assessment of the morphology of the nucleated cells. The present disclosure is further based, in part, on the discovery that CECs can be detected in non-enriched blood samples by comparing the immunofluorescent marker staining and morphological characteristics of CECs with the immunofluorescent marker staining and morphological characteristics of WBCs. The methods disclosed herein serve to classify human subject in myocardial infarction (MI) patients or healthy controls.

This invention provides a means to obtain more clinically useful information when analyzing particles contained in blood samples using metachromatic positive dyes. In a particle analysis method for analyzing particles contained in blood samples, particles are stained with a metachromatic positive dye; the stained particles are irradiated with light; the intensity of a first fluorescence from the stacking component of the metachromatic positive dye and the intensity of a second fluorescence from the embedded component of the metachromatic positive dye are measured, the first and second fluorescence being emitted by each particle contained in the blood sample; the intensities of the first and second fluorescence emitted by each particle are normalized according to the size of each particle to obtain the fluorescence concentration of each of the first and second fluorescence in each particle; in a two-dimensional plot of the normalized fluorescence concentrations, each particle is clustered into multiple particle clusters, including at least two of erythrocyte clusters, platelet clusters, and nucleated cell clusters; and a histogram is created where the intensity of the first fluorescence is a histogram of the RNA amount of the class and the intensity of the second fluorescence is a histogram of the DNA amount of the class included in at least one of the multiple particle clusters.

Disclosed is a computer-implemented method of analyzing bone marrow fluid, including counting the number of nucleated cells and the number of lipid particles in a bone marrow fluid; and obtaining an index related to bone marrow nucleated cell density, on the basis of the number of nucleated cells and the number of lipid particles.

A method for obtaining enucleated cells from nucleated cells is described herein. A cell processing method is also described herein, which includes providing a composition containing nucleated cells and enucleating at least a portion of the nucleated cells to produce an enucleated cell fraction.

Described herein are methods for obtaining enucleated cells from nucleated cells. Also described herein are methods for cell processing, including providing a composition containing nucleated cells and enucleating at least a portion of the nucleated cells to produce an enucleated cell fraction. Also described herein are methods for cell processing, including expressing the heterologous gene product. Also provided are pharmaceuticals compositions comprising an enucleated cell.

The application discloses a blood separation method and a separation device, relates to the field of blood separation, and needs to use a blood separation device, wherein the blood separation device comprises a centrifugal device and a separation tube; the separation tube is in circular motion with the rotation center of the centrifugal device as the center during use; the separation tube comprises a blood inlet, a plasma outlet, a red blood cell outlet and a nucleated cell outlet; the plasma outlet is located at one end close to the rotation center; the red blood cell outlet and the nucleated cell outlet are located at one end away from the rotation center; blood is continuously injected into the blood inlet after the movement of the separation tube, and the plasma, the red blood cells and the nucleated cells in the separation tube continuously or intermittently flow out when the volumes of the plasma, the red blood cells and the nucleated cells reach a separation threshold value during the period. Compared with the prior art, the application adopts a continuous centrifugal method to separate various components in blood by guaranteeing a centrifugal sedimentation distance, so that the separation effect is obviously improved, and the actual effect is very remarkable.

The invention discloses a myeloma minimal residual disease intelligent diagnosis system based on cell morphological characteristics, and the system comprises a bone marrow cell image input module which is used for receiving a nucleated cell segmentation image and then carrying out data enhancement processing on the nucleated cell segmentation image for the purpose of generating more diversified image samples; and the myeloma plasma cell intelligent classification module is internally provided with a nucleated cell and plasma cell classification model and is used for receiving the nucleated cell segmentation image subjected to data enhancement, identifying normal plasma cells and myeloma plasma cells from the nucleated cell segmentation image and calculating the percentage of the normal plasma cells and the myeloma plasma cells. The artificial intelligence technology is applied to myeloma minimal residual disease detection based on bone marrow blood cell morphology, the myeloma minimal residual disease diagnosis system which is low in cost, high in accuracy and high in detection speed can be achieved, additional blood sample collection does not need to be conducted on a patient, the acceptance degree of the patient is high, and the pain degree is low; wide medical scientificity and clinical application prospects are realized.

The present disclosure is directed to the stabilization of nucleated cells in a whole blood sample ex-vivo, effected by an additive being a liquid composition for stabilizing an analyte in intact nucleated cells of a whole-blood sample ex-vivo, the composition being an aqueous solution, the solution comprising an anticoagulant, a phosphate salt, a cell-metabolizable sugar, adenine, and an antioxidant, wherein the antioxidant comprises a mitochondria-targeted antioxidant, preferably a mitochondria-targeted antioxidant selected from the group consisting of SkQ1, MitoQ, SS-31, and a mixture thereof. In a specific embodiment, the liquid composition further comprises a protease inhibitor. Further provided is advantageous use of the composition for stabilizing an analyte selected from DNA, RNA and protein in intact nucleated cells of the whole-blood sample ex-vivo, as well as kits including the composition for practicing said use. Additionally, specific methods are provided for stabilizing intact nucleated cells of a whole-blood sample ex-vivo.

The utility model discloses a mononuclear cell separation bag, the open end of a whole blood sample bag is provided with a liquid one-way flow conduit and is connected with a blood sample transfer conduit, a plasma transfer conduit and a blood cell transfer conduit, the whole blood sample bag is connected with a plasma bag through the plasma transfer conduit, the open end of the plasma bag is provided with the liquid one-way flow conduit, and the blood cell transfer conduit is connected with the blood cell transfer conduit. The blood sample transfer catheter is connected with the plasma transfer catheter and the blood cell transfer catheter, the other end of the blood cell transfer catheter is connected with the blood cell transfer catheter, the other end of the blood cell transfer catheter is connected with the blood cell transfer bag, the open end of the blood cell transfer bag is provided with a sample extraction port, and the blood sample transfer catheter, the plasma transfer catheter and the blood cell transfer catheter are provided with disposable pipeline plugging devices and pipeline temporary sealing devices. The disposable closed container is used, so that the centrifugal tube is prevented from being frequently replaced, and meanwhile, the experiment failure caused by sample pollution due to the fact that hands of operators or articles pass through the upper part of the open centrifugal tube is also avoided.

Described herein are methods for obtaining enucleated cells from nucleated cells. Also, described herein are methods for cell processing, including providing a composition containing nucleated cells and enucleating at least a portion of the nucleated cells to produce an enucleated cell fraction.

The present invention provides a method for cell analysis, comprising: preparing a blood sample comprising nucleated cells having surface, cytoplasmic or nuclear antigens (markers); antibody staining the cell markers; fixing and permeabilising the cells; FISH probe hybridising to chromosomes in the cells; performing imaging flow cytometry on the cells; analysing data obtained from performing imaging flow cytometry; and diagnosing, prognosing or monitoring a medical condition based on the data analysis.

The utility model discloses a kind of nucleated cell kit canning device, it is related to reagent kit packaging technical field.The utility model includes support frame, further include: support part, the support part is set on support part;Filling part, the filling part is set on the top of support part;And blanking part, the blanking part is set on support part;Wherein, the bottom of support frame is equipped with motor slot, and the structure on the filling part is compatible with this motor slot.The utility model sets up filling part, when using, operating personnel first places the reagent kit to be filled in on feed conveyor belt, feed conveyor belt is sequentially conveyed to equidistant turntable according to pre-set program, at this time, motor one starts, and equidistant turntable is rotated by rotating shaft one drive, to avoid interference, feed conveyor belt pauses conveying during equidistant turntable operation, ensure that equidistant turntable can move reagent kit to the just below of adjusting plate on feed hopper.

A kind of children's leukemia multi-instance classification method based on hierarchical attention mechanism, first, carry out cell segmentation task: the nucleated cell in the multiple bone marrow cell images of children's leukemia patient is extracted by cell segmentation module, and the random sampling of N cells is formed into a multi-instance package as sample input learning;Second, carry out children's leukemia classification task: the above input sample after learning is used as children's leukemia classification module, distinguish each sample belongs to acute myeloid leukemia, or acute lymphoid leukemia, and further carry out multiple hierarchical typing;The method of the present application uses multi-instance learning, encodes cells into features, and calculates the contribution of different cells to each category through the attention module, and forms hierarchical features by typing, from the attention matrix of subtyping to the coarse typing, for the loss function of cancer cell proportion, by limiting the proportion, semi-supervisedly classifies whether each cell belongs to cancer cell, so that the attention mechanism can better calculate the contribution of cells to each category, so that the classification is more accurate.

The disclosure provides a method of identifying a cell type, or the presence or absence of a cell type, associated with response to abiraterone or enzalutamide in a cancer patient, comprising (a) performing a direct analysis comprising immunofluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) isolating the CTCs from the sample; (c) individually characterizing parameters to generate a profile for each of the CTCs, and (d) identifying a biomarker CTC, wherein presence or absence of the biomarker CTC indicates a responsiveness in the patient to abiraterone or enzalutamide.

The invention relates to the technical field of sample preservation. The invention provides an exfoliated cell preserving fluid and a preparation method and application thereof, the preserving fluid comprises a cracking agent, a buffering agent, a chelating agent, a mucus dissolving agent and a preservative, the cracking agent and the buffering agent comprise ammonium salt, and the ammonium salt comprises at least one selected from the group consisting of ammonium chloride, ammonium acetate and ammonium bicarbonate. The preserving fluid can selectively lyse red blood cells to reduce blood background interference, and strongly disperse and dissolve mucus to effectively release wrapped target cells; the morphological integrity and nucleic acid integrity of nucleated cells are protected, and morphological abnormalities such as solid shrinkage, dissolution or expansion of the cells are avoided. The biological stability of the sample in the long-term storage and transportation process is ensured due to strong anti-corrosion and antibacterial capabilities; the preservation solution can meet the requirements of cell morphology examination and molecular detection at the same time, double-detection compatibility is achieved, the preparation technology is simple and convenient, and large-scale production is easy to achieve.

The present invention discloses a cell scaffold for promoting bone tissue regeneration in the femoral head necrosis region, wherein a drug with mesenchymal stem cells and bone marrow nucleated cells as effective ingredients is attached to the cell scaffold; wherein the concentration of the mesenchymal stem cells is 5×10 5 ‑1×10 6 / cm 3 The concentration of bone marrow nucleated cells is 5×10 5 ‑1×10 6 / cm 3 The cell scaffold for promoting bone tissue regeneration in the necrotic area of ​​the femoral head of the present invention can significantly improve the blood supply in the femoral head of the femoral head necrosis, reduce the formation of the necrotic area, promote bone regeneration in the necrotic area, improve the bone density in the necrotic area, and provide a new treatment strategy for the treatment of femoral head necrosis.

The invention provides a human blood tumor minimal residue monitoring model, which belongs to the field of biotechnology, and comprises a data acquisition module, which is used for receiving DNA sequencing data before and after treatment; the nucleated cell number acquisition module is used for acquiring the nucleated cell number; the clone atlas and sequence acquisition module is used for acquiring a clone atlas and a corresponding sequence; the fused genotype and sequence acquisition module is used for acquiring a fused genotype and a corresponding sequence; the calculation module is used for calculating the clone frequency, the clone cell content, the fusion frequency and the fusion cell content, and determining a significant clone type and a significant fusion type based on the clone frequency, the clone cell content, the fusion frequency and the fusion cell content; and the MRD calculation and judgment module is used for calculating an MRD value and judging the residual state of the disease according to the MRD value. The library can be obtained only through one round of PCR amplification, the library building time is remarkably shortened, and the lowest detection limit can reach 10 <-7 >.

Methods for obtaining enucleated cells from nucleated cells are described herein. Methods for cell processing, comprising providing a composition containing nucleated cells and enucleating at least a portion of nucleated cells to produce an enucleated cell fraction, are also described herein. Methods for cell processing, comprising expressing heterologous gene products, are also described herein. Pharmaceutical compositions containing enucleated cells are also provided.

The present invention provides a monitoring model for minimal residual disease of human hematological malignancies, belonging to the field of biotechnology, including: a data acquisition module for receiving DNA sequencing data before and after treatment; a nucleated cell count acquisition module for obtaining the nucleated cell count; a clone map and sequence acquisition module for obtaining the clone map and the corresponding sequence; a fusion genotype and sequence acquisition module for obtaining the fusion genotype and the corresponding sequence; a calculation module for calculating the clone frequency, the clone cell content, the fusion frequency and the fusion cell content, and determining the significant clone type and the significant fusion type based on the clone frequency, the clone cell content, the fusion frequency and the fusion cell content; an MRD calculation and determination module for calculating the MRD value and determining the residual status of the disease according to the MRD value. Only one round of PCR amplification is required to obtain the library, significantly shortening the library construction time, and the lowest detection limit can reach 10 ‑7 .

Provided is a use of a histone deacetylase (HDAC) inhibitor and / or JAK2 inhibitor in inducing hematopoietic stem progenitor cells, mononuclear cells or total nucleated cells to generate megakaryocytes and / or megakaryocyte progenitor cells. Also provided is a method for inducing hematopoietic stem progenitor cells, mononuclear cells or total nucleated cells to generate megakaryocytes and / or megakaryocyte progenitor cells, comprising exposing the cells to an HDAC inhibitor and / or exposing the cells to a JAK2 inhibitor.

Methods and compositions useful for delivering a protein to a plurality of nuclei in a cell. Fusion proteins comprising one or more signals useful for promoting delivery of the proteins to a plurality of nuclei in a multinucleate cell. Methods comprising administering isolated nucleic acids to a multinucleate cell, wherein the isolated nucleic acid comprises a sequence encoding a fusion protein, the fusion protein comprising, a protein of interest fused to at least the following migration signals: (a) at least one nuclear export signal (NFS); and (b) at least one nuclear localization signal (NLS) and / or at least one nucleolar localization signal (NoLS). Fusion proteins comprising: (a) a protein of interest; and (b) at least the following migration signals: (i) a nuclear export signal (NFS); (ii) a nuclear localization signal (NLS); and (iii) a nucleolar localization signal (NoLS). Methods of making and using the same. Methods of delivering recombinant genes and / or fusion proteins to multinucleate cells.

The disclosure provides a method of detecting heterogeneity of disease in a cancer patient comprising (a) performing a direct analysis comprising immuno fluorescent staining and morphological characterization of nucleated cells in a blood sample obtained from the patient to identify and enumerate circulating tumor cells (CTC); (b) isolating the CTCs from the sample: (c) individually characterizing genomic parameters to generate a genomic profile for each of the CTCs, and (c) determining heterogeneity of disease in the cancer patient based on the profile. In some embodiments, the cancer is prostate cancer. In some embodiments, the prostate cancer is hormone refractory.